24-Months results in two adults with Pompe disease on enzyme replacement therapy

Clinical Neurology and Neurosurgery

Volumn 113, Issue 5, 2011, Pages 350-357

  Vielhaber, Stefan ^a   Brejova, Andrea ^a   Debska Vielhaber, Grazyna ^a   Kaufmann, Joern ^a   Feistner, Helmut ^a   Schoenfeld, Mircea A ^a   Awiszus, Friedemann ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Acid alpha glucosidase; Dynamometer; Enzyme replacement therapy; Glycogenosis type II; Isometric tourque measurement; Pompe disease

Indexed keywords

RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;

ADULT; ARTICLE; CASE REPORT; DATA BASE; DISEASE DURATION; DYNAMOMETER; ENDURANCE; ENZYME REPLACEMENT; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; LUNG VENTILATION; MALE; MUSCLE STRENGTH; PATIENT ASSESSMENT; WALKING DIFFICULTY;

ADULT; AGE OF ONSET; ALPHA-GLUCOSIDASES; CREATINE KINASE; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; FEMALE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; ISOMETRIC CONTRACTION; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MENTAL HEALTH; MUSCLE STRENGTH; MUSCLE, SKELETAL; NEUROLOGIC EXAMINATION; PAIN; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SPIROMETRY; THIGH; TREATMENT OUTCOME; WALKING;

EID: 79955840562     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2010.09.016     Document Type: Article

References (36)

1. DiMauro S, Lamperti C. Muscle glycogenoses. Muscle Nerve 2001;24:984-99. (Pubitemid 32656185)
2. Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005;128:671-7. (Pubitemid 40380201)
3. Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, et al. The natural course of non-classic Pompe's disease, a review of 225 published cases. J Neurol 2005;252:875-84. (Pubitemid 41186956)
4. Engel AG, Hirschhorn R. Metabolic disorders affecting muscle. Acid maltase deficiency. In: Myology. 2nd ed. New York: McGraw-Hill; 1994. p. 1533-1553.
5. Mellies U, Ragette R, Schwake C, Baethmann M, Voit T, Teschler H. Sleep-disordered breathing and respiratory failure in acid maltase deficiency. Neurology 2001;57:1290-5. (Pubitemid 32947390)
6. Van der Beek NA, Hagemans ML, Reuser AJ, Hop WC, Van der Ploeg AT, Van Doorn PA, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 2009;19: 113-7.
7. Müller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, et al. Late-onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 2007;17:698-706. (Pubitemid 47362681)
8. Wokke JH, Escolar DM, Pestronk A, Jaffe KM, Carter GT, van den Berg LH, et al. Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 2008;38:1236-45.
9. van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010;362:1396-406.
10. Reuser AJ, Kroos MA, Hermans MM, Bijvoet AG, Verbeet MP, Van Diggelen OP, et al. Glycogenosis type II (acid maltase deficiency). Muscle Nerve 1995;3:61-9.
11. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007;68:99-109.
12. Klinge L, Straub V, Neudorf U, Voit T. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. Neuropediatrics 2005;36:6-11. (Pubitemid 41115324)
13. Klinge L, Straub V, Neudorf U, Schaper J, Bosbach T, Görlinger K, et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantilePompedisease: results of a phase II clinical trial. Neuromuscul Disord 2005;15:24-31. (Pubitemid 41556629)
14. Van Capelle CI, Winkel LP, Hagemans ML, Shapira SK, Arts WF, van Doorn PA, et al. Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord 2008;18:447-52.
15. Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, et al. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 2004;55:495-502. (Pubitemid 38391966)
16. Becker R, Awiszus F. Physiological alterations of maximal voluntary quadriceps activation by changes of knee joint angle. Muscle Nerve 2001;24: 667-72. (Pubitemid 32373029)
17. Berth A, Urbach D, Neumann W, Awiszus F. Strength and voluntary activation of quadriceps femoris muscle in total knee arthroplasty with midvastus and subvastus approaches. J Arthroplasty 2007;22:83-8. (Pubitemid 46014046)
18. Rossi M, Parenti G, Della Casa R, Romano A, Mansi G, Agovino T, et al. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from Chinese hamster ovary cells. J Child Neurol 2007;22:565-73. (Pubitemid 46951500)
19. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 1981;4:186-97.
20. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87. (Pubitemid 29036522)
21. American Thoracic Society (ATS). ATS statement: lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Disease 1991;144:1202-18.
22. Bullinger M. German translation and psychometric testing of the SF-36 Health Survey: preliminary results from the IQOLA Project. International Quality of Life Assessment. Soc Sci Med 1995;41:1359-66.
23. Hagemans ML, Janssens AC, Winkel LP, Sieradzan KA, Reuser AJ, Van Doorn PA, et al. Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology 2004;63:1688-92. (Pubitemid 39507589)
24. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 1992;30:473-83.
25. Ware Jr JE. The SF-36 health survey. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven; 1996. p. 337-345.
26. Becker R, Berth A, Nehring M, Awiszus F. Neuromuscular quadriceps dysfunction prior to osteoarthritis of the knee. J Orthop Res 2004;22:768-73. (Pubitemid 38756255)
27. Case LE, Koeberl DD, Young SP, Bali D, DeArmey SM, Mackey J, et al. Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: a case study. Mol Genet Metab 2008;95:233-5.
28. Merk T, Wibmer T, Schumann C, Krüger S. Glycogen storage disease type II (Pompe disease)-influence of enzyme replacement therapy in adults. Eur J Neurol 2009;16:274-7.
29. Pichiecchio A, Uggetti C, Ravaglia S, Egitto MG, Rossi M, Sandrini G, et al. Muscle MRIin adult-onset acid maltase deficiency. Neuromuscul Disord 2004;14:51-5. (Pubitemid 37498223)
30. Laforêt P, Nicolino M, Eymard PB, Puech JP, Caillaud C, Poenaru L, et al. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 2000;55:1122-8.
31. van der Ploeg AT. Monitoring of pulmonary function inPompedisease: a muscle disease with new therapeutic perspectives. Eur Respir J 2005;26:984-5. (Pubitemid 41829925)
32. McHorney CA, Ware Jr JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994;32:40-66.
33. Dudeney S, Lieberman IH, Reinhardt MK, Hussein M. Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol 2002;20:2382-7. (Pubitemid 34441668)
34. Kiebzak GM, Campbell M, Mauerhan DR. The SF-36 general health status survey documents the burden of osteoarthritis and the benefits of total joint arthroplasty: but why should we use it? Am J Manag Care 2002;8:463-74. (Pubitemid 34552325)
35. McKee MD, Yoo D, Schemitsch EH. Health status after Ilizarov reconstruction of post-traumatic lower-limb deformity. J Bone Joint Surg Br 1998;80:360-4.
36. Wokke JH, Ausems MG, van den Boogaard MJ, Ippel EF, van Diggelene O, Kroos MA, et al. Genotype-phenotype correlation in adult-onset acid maltase deficiency. Ann Neurol 1995;38:450-4.